Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.70%
As of Thursday, October 29, OnKure Therapeutics, Inc.’s OKUR share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Commentary & Analysis
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Up 8.69%
As of Tuesday, October 27, OnKure Therapeutics, Inc.’s OKUR share price has surged by 8.69%, which has investors questioning if this is right time to sell.Michael Rose
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Up 8.00%
As of Tuesday, October 20, OnKure Therapeutics, Inc.’s OKUR share price has surged by 8.00%, which has investors questioning if this is right time to sell.Michael Rose
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.53%
As of Thursday, October 08, OnKure Therapeutics, Inc.’s OKUR share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 7.52%
As of Thursday, October 01, OnKure Therapeutics, Inc.’s OKUR share price has dipped by 7.52%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $104.9 | $227.3 | 23% |
|
| Shares Out (Mil) | 49.9 | 53.4 | 47% |
|
| Institutional Ownership | 83.0% | 92.9% | 51% |
|
| Float (Mil) | 18.7 | 41.4 | 28% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 368 | 468 | 53% |
|
| Price Change (52-week) |
(20.8%) | 47.4% | 34% |
|
| Growth | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.410) | ($1.830) | ($1.527) | |
| Month Ago EPS | ($0.410) | ($1.830) | ($1.527) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 3 | 3 | |
| Three Months Ago EPS | ($0.465) | ($1.955) | ($1.960) | |
| Year/Year Chg | 33.1% | (58.4%) | (62.4%) | |
| Financials | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($59) | ($44) | 15% |
|
| EPS (TTM) | ($2.584) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($48) | ($34) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $83 | $1 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($22) | $174 | 1% |
|
| Valuation | OKUR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.61 | 2.14 | 13% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (69.8%) | na |
|
| ROA | (44.2%) | (47.1%) | 13% |
|
| ROE | (46.9%) | (52.0%) | 16% |
|
| Liabilities to Assets | 4.0% | 29.7% | 2% |
|
| F-Score | 4 | 2 | 33% |
|
OnKure Therapeutics, Inc. did not pass any screens on 11/4/2026.
